



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 21 Nov 2022 (#44)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

**To prepare an application can take 4-18 months, depending on many factors:**

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Important Notices

**International Community Access to Child Health (ICATCH) is a highly dedicated team of paediatricians from US and around the world working together to provide funding for paediatric community health projects to healthcare partners in low-income and low-middle-income countries.** Each year, ICATCH awards up to 3-year grants worth \$2000 per year to up to 7 healthcare providers or educators working to advance child health. [The application for the 2023-2026 grant cohort is now open.](#) **Preliminary applications deadline: Friday, 9 December 2022**

[The Visitor Training Program \(VTP\)](#) of the [American Society of Haematology](#) is designed to help build haematology capacity in [low- and middle-income countries](#) by providing funding for haematologists and haematology-related health care professionals in these regions to receive up to 12 weeks of training on a specific topic or technique. Training is designed to address a specific haematology need and is carried out in the clinic or laboratory of an ASH member, under their supervision and mentorship. The 2023 Visitor Training Program is [now open](#). **Application deadline: 16 December 2022**

[The Takemi Program in International Health](#) at the Harvard T.H. Chan School of Public Health is accepting applications from mid-career professionals for fellowships focusing on mobilizing, allocating, and maintaining limited resources to improve health and health systems. [Takemi Booklet](#). Application deadline: 31 December 2022.

[The Union for International Cancer Control \(UICC\)](#) is accepting applications for [Technical Fellowships](#) for the transfer of cancer control knowledge, skills, and techniques through one-month international visits. Applications are accepted until 31 December 2022. After this date the next opportunity to apply will be 1st February 2023. Eligible candidates are cancer professionals such as cancer advocates, public health investigators, implementation and translational researchers, pathologists, epidemiologists, tobacco control activists and cancer registrars in the early stages of their careers who hold at least an MSc or MA. In addition, clinicians and nurses who are established in oncology practice and hold as a minimum an MD degree (for doctors) or RN (for nurses) are eligible to apply. While candidates working in all fields of cancer control are welcome to apply, applications in cancer prevention and early detection, breast cancer (as part of the broader [Breast Cancer Programme](#)) and [cancer and ageing](#) are particularly encouraged. [Application guideline and general conditions](#)

[No-Cost Extensions](#) Do you wish you had more time at the end of a project? You could benefit from an extension and, you may consider requesting a no-cost extension (NCE). What is a NCE? It is an extension of time to a project period or budget period to complete the work of the grant under that period, without additional federal funds or competition. Be aware: in some situations an NCE is not allowed. To find out whether that's the case for you, check the terms on your Notice of Award.

[Gearing Up for Transition to FORMS-H Application Forms](#): As [announced](#) over the summer, NIH requires the use of updated application forms (FORMS-H) for due dates on or after January 25, 2023. . The [How to Apply – Application Guide](#) was updated on October 25 with FORMS-H application form instructions to prepare for the transition. Also see [Guide Notice NOT-OD-23-012](#). All form changes are listed in [High-level Grant Application Form Change Summary: FORMS-H](#). A key change in FORMS-H is support for the implementation of the 2023 [NIH Data Management and Sharing Policy](#).

The intended due date for your application determines the correct form version to use.

- DO use FORMS-G form version for application due dates on or before January 24, 2023
- DO use FORMS-H form version for application due dates on or after January 25, 2023
- DO NOT use FORMS-H too early or FORMS-G too late

[NOT-DA-22-064](#) Notice of Intent to Publish a Funding Opportunity Announcement for NIH Brain Development Cohorts Biospecimen Access (X01 Clinical Trial Not Allowed). The National Institute on Drug Abuse intends to promote a new resource access program by publishing a Funding Opportunity Announcement (FOA) to seek applications for the following: NIH Brain Development Cohorts (NBDC) Biospecimen Access Program (X01- Clinical Trial Not Allowed). This FOA will allow investigators to apply for access to biological samples from the Adolescent Brain Cognitive Development<sup>SM</sup> (ABCD) Study. By making these specimens available to the greater scientific community, this resource award seeks to maximize the scientific potential of the biospecimens collected in the ABCD Study<sup>®</sup> and expand the scope of ABCD's open science model, allowing scientists from around the world to utilize these specimens and enrich the child and adolescent health data being obtained from the ABCD Study. No funds will be provided through this opportunity. Applicants will be responsible for costs associated with conducting the research and sample shipment. Applicants will need to submit proof of funding for costs of analyses and sample shipment at the time of application.

[NOT-MH-23-135](#) Notice of Intent to Publish a Funding Opportunity Announcement for Bidirectional Influences Between Adolescent Social Media Use and Mental Health (R01 Clinical Trial Optional). The National Institute of Mental Health (NIMH) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for research on bidirectional influences between social media use and adolescent mental health, psychiatric symptoms, and risk or resilience for psychopathology. Adolescents have increasing access to and spend an increasing amount of time engaging in online social interactions and consuming content on social media platforms, yet there is limited knowledge of how online social behavior and experiences interact with adolescent mental health and risk for psychopathology. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in January 2023 with an expected application due date in March 2023. See notice [NOT-MH-23-136](#) for R21 information.

## Notices of Special Interest (NOSI)

**[NOT-DA-24-002](#) Chemsex and HIV: prevalence, medical/psychosocial consequences, and treatment. Chemsex is the use of drugs during sexual activity to sustain or enhance sexual pleasure.** This practice has been reported as an addictive behavior, though little is known about prevalence, medical/psychosocial consequences, preventive measures and treatment of chemsex. The purpose of this notice is to support research on the epidemiology, medical/psychosocial impact, and preventive and therapeutic measures for chemsex in people with HIV and HIV-vulnerable populations including sexual minorities (SM) e.g. lesbian, gay, bisexual. NIDA is interested in studies focusing on: 1. Epidemiology; 2. Acute and long-term medical consequences, and the psychosocial implications of chemsex in the context of HIV, with focus on HIV-most vulnerable populations; 3. Developing safe and effective pharmacological and non-pharmacological interventions for prevention and therapy and 4. Optimizing existing evidence-based interventions for key populations of interest. NIDA is interested in studies focusing on: 1. Epidemiology; 2. Acute and long-term medical consequences, and the psychosocial implications of chemsex in the context of HIV, with focus on HIV-most vulnerable populations; 3. Developing safe and effective pharmacological and non-pharmacological interventions for prevention and therapy and 4. Optimizing existing evidence-based interventions for key populations of interest. This notice applies to due dates on or after January 5, 2023 and subsequent receipt dates through January 8, 2026. Submit applications for this initiative using one of the funding opportunity announcements (FOAs) listed in the notice.

**[NOT-OD-23-018](#) Administrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues (Admin Supp Clinical Trial Optional).** Related Announcements: [NOT-OD-22-026](#) - Notice of Special Interest (NOSI): Administrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues (Admin Supp Clinical Trial Optional). The NIH Office of Science Policy (OSP) within the Office of the Director (OD) announces the availability of administrative supplements to support 1) research on bioethical issues to develop or support the development of an evidence base that may inform future policy directions, and/or 2) certain efforts to develop or augment bioethics research capacity. Applicants may propose to supplement parent awards focused on bioethics or to address a component related to bioethics in a biomedical and/or health-related behavioral research study. **Note that applications must be within the general scope of the parent award.** Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent: [PA-20-272](#) - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional). **Application Due Date: 17 Feb 2023** by 5:00 PM local time of applicant organization. Application budget cannot exceed a maximum direct cost of \$200,000. In addition to the direct cost, applicable F&A (indirect) costs can also be requested. Requests may be for one year of support only.

## Funding Opportunity Announcements (FOA)

### 1. Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-033](#)

**Type:** U19

**Application Due Date:** March 15, 2023; March 15, 2024; March 14, 2025. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to support translation of advanced HIV-1 vaccine candidates from pre-clinical studies through different phases of process and product development, Current Good Manufacturing Practice (CGMP) manufacturing and regulatory filing to the point of clinical testing. The FOA will support technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership with Pharma/Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability testing programs, Investigational New Drug (IND)-enabling studies, and regulatory submission preparation.

**Budget:** The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NIAID intends to commit at least \$4M in FY 2024 to fund 1-2 awards. Application budgets are limited to \$3,000,000 direct costs per year for the 1st and 2nd years of award. Application budgets need to reflect the actual needs of the proposed program. The project period is up to five years.

**2. Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)**

**Letter of Intent: 30 days prior to the application due date**

**Hyperlink: [RFA-DA-24-002](#)**

**Type: R61/R33**

**Application Due Date:** Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory studies that 1) develop or apply novel tools or technologies or 2) test novel hypotheses to investigate mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including neuroHIV) in the context of Substance Use Disorders (SUDs). This initiative focuses on exploration and characterization of signalling pathways that are involved in CNS HIV establishment and expansion. The FOA aims to promote research to investigate the underlying molecular mechanisms by which HIV infection is initiated, established, and maintained in the CNS and to determine how addictive substances modulate HIV infection, latency and the size and persistence of CNS HIV reservoirs.

**Budget:** NIDA intends to support up to 6 awards, corresponding to a total of \$ 3,000,000 in FY 2024. Future year amounts will depend on annual appropriations. Applications may not request more than \$350k direct costs for any single year of the R61 phase or more than \$500k direct costs for any single year of the R33 phase. The maximum period of the combined R61/R33 is five years, with up to two years for the R61 Phase and three years for the R33 Phase. Funding of the R33 award will be determined by successful completion of the R61 scientific goals, as determined by NIH.

**Research Development and Support Division (RDSD) &  
Grants Management Office (GMO)  
Faculty of Medicine and Health Sciences  
K<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838**

**Division for Research Development (DRD)  
Stellenbosch Campus  
2041 Krottoa Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105**